TABLE 2.

Confirmed objective response rate and duration of response

	APP (n = 82)	PP (n = 81)
Objective response rate	46 (56.1)	22 (27.2)
Difference (95% CI), %	28.9 (13.3, 44.6)
Complete response	0	0
Partial response	46 (56.1)	22 (27.2)
Stable disease	27 (32.9)	40 (49.4)
Progressive disease	4 (4.9)	9 (11.1)
Duration of response, median (95% CI), mo	6.7 (5.7, 8.0)	8.5 (4.2, NE)
Responders without event	16 (34.8)	10 (45.5)

Note: Data are n (%) except where otherwise indicated. Five patients in the APP arm and 10 patients in the PP arm were classified as missing or unevaluable for response. Data cutoff was July 18, 2019.

Abbreviations: APP, atezolizumab plus cisplatin plus pemetrexed; NE, not evaluable; PP, cisplatin plus pemetrexed.